RxDoctor Payments Data

Sherry Sood, MD

Internal Medicine · Pasadena, MDNPI 1073613972

Payments from drug & device makers

$6,245in general payments, 2019–2025

Across 327 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$788
  • Novo Nordisk$371
  • Lilly USA, LLC$353
  • Amgen$351
  • Takeda Pharmaceuticals U.S.A., Inc.$345
  • Pfizer$295
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$6,14698%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)62$788
Novo Nordisk21$371
Lilly USA, LLC19$353
Amgen(2 entities)15$351
Takeda Pharmaceuticals U.S.A., Inc.10$345
Pfizer13$295
Lundbeck LLC13$262
Argenx US, Inc.8$247
UCB, Inc.10$189
Novartis10$184
AstraZeneca(2 entities)7$162
Biohaven Pharmaceutical Holding Company Ltd.14$156
Acadia Pharmaceuticals Inc7$132
SK Life Science, Inc.5$124
Neurelis, Inc.6$118
Johnson & Johnson(2 entities)2$114
Teva Pharmaceuticals USA, Inc.5$110
Eisai Inc.4$95
Jazz Pharmaceuticals Inc.5$91
Grifols USA, LLC5$90
Impel Pharmaceuticals Inc.4$87
Harmony Biosciences LLC3$81
Axsome Therapeutics, Inc.3$70
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$68
Adamas Pharmaceuticals, Inc.4$68
Catalyst Pharmaceuticals, Inc.3$59
Sanofi3$58
Astellas Pharma US Inc3$56
Upsher-smith Laboratories LLC2$55
CSL Behring3$54
Banner Life Sciences, LLC3$53
Neos Therapeutics, LP3$53
Tanabe Pharma America, Inc.2$49
Avanir Pharmaceuticals, Inc.3$43
Vanda Pharmaceuticals Inc.2$43
GSK2$40
Sunovion Pharmaceuticals Inc.2$40
Kedrion Biopharma, Inc.2$38
Life Molecular Imaging Ltd1$34
EMD Serono, Inc.2$32
Biohaven Pharmaceuticals, Inc.2$32
Biogen2$32
Neurocrine Biosciences, Inc.1$31
ANI Pharmaceuticals, Inc.1$29
Sanofi-aventis U.S. LLC2$28
Almatica Pharma LLC1$27
Shire North American Group Inc1$26
Ironwood Pharmaceuticals, Inc2$24
Dexcom, Inc.1$23
Avadel CNS Pharmaceuticals, LLC1$23
Xeris Pharmaceuticals, Inc.1$21
Nevro Corp.1$21
Boehringer Ingelheim1$21
Vertos Medical, Inc.1$21
Mannkind Corporation1$21
Valeritas, Inc.1$19
Currax Pharmaceuticals LLC1$18
Exact Sciences1$17
Arbor Pharmaceuticals, Inc.1$17
Insulet Corporation1$16

How this compares

$6,245 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$96,743
Medicare patients
229
Services billed
848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide133$293,724
MounjaroTirzepatide138$248,874
EliquisApixaban47$63,850
JardianceEmpagliflozin50$54,290
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$39,581
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$39,412
JanuviaSitagliptin Phosphate32$38,337
XareltoRivaroxaban28$37,032
VraylarCariprazine Hcl17$23,934
Tresiba Flextouch U-200Insulin Degludec18$20,830
Victoza 3-PakLiraglutide14$18,410
TradjentaLinagliptin15$17,682
LinzessLinaclotide14$15,419
MyrbetriqMirabegron12$14,064
Tresiba Flextouch U-100Insulin Degludec18$10,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$371$293,724133 claims
Lilly USA, LLCMounjaro$353$248,874138 claims
Boehringer IngelheimJardiance, Tradjenta$21$71,97265 claims
PfizerEliquis$295$63,85047 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$40$49,64657 claims
AbbVieVraylar, Linzess$788$39,35331 claims
Johnson & JohnsonXarelto$114$37,03228 claims
Astellas Pharma US IncMyrbetriq$56$14,06412 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$17$5,11111 claims
Almatica Pharma LLCSertraline Hcl$27$1,478124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Pasadena

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →